Global Burden of Elevated LDL-C
JAMA · 25.08.2026 · 336 (8) · 673
DOI: 10.1001/jama.2026.8628 ↗Kurz gefasst
Metaanalyse in der Zeitschrift JAMA, erschienen am 25.08.2026. Verfasst von GBD 2023 LDL Cholesterol Collaborators und 59 weiteren Autor:innen. Beteiligte Einrichtung: Institute for Health Metrics and Evaluation (IHME), University of Washington, Seattle, Washington. Hauptthemen laut MEDLINE: Cholesterol, LDL, Global Burden of Disease, Hypercholesterolemia, Ischemic Stroke. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: World Health Organization.
Abstract (Originalsprache)
Importance Elevated low-density lipoprotein cholesterol (LDL-C) is a modifiable risk factor for cardiovascular disease, the leading cause of premature death worldwide. Assessing the LDL-C–related burden is critical for guiding prevention and treatment strategies.
Objectives
To estimate the global, regional, and national burden of ischemic heart disease and ischemic stroke attributable to elevated LDL-C (relative to 35-54 mg/dL) from 1990 to 2023 and to quantify the contributions of population growth, aging, risk-deleted burden, and exposure changes to burden trends. Design, Setting, and Population This comparative risk assessment, part of the Global Burden of Disease Study 2023, estimated population-level LDL-C exposure and associated health loss in 204 countries and territories. Mean LDL-C levels were estimated using spatiotemporal gaussian process regression based on 806 studies across 161 countries. Relative risks were derived from meta-analyses of 38 randomized clinical trials. Population-attributable fractions for deaths and disability-adjusted life-years (DALYs) were estimated by age and sex for adults aged 25 years or older from 1990 to 2023, with 95% uncertainty intervals. Exposure Population-level LDL-C concentrations. Main Outcomes and Measures Population-attributable fractions, counts, and rates (all ages and age standardized per 100 000) of LDL-C–attributable deaths and DALYs from ischemic heart disease and ischemic stroke, with uncertainty intervals.
Results
In 2023, elevated LDL-C accounted for 3.6 million deaths (95% uncertainty interval, 2.2-5.4 million; 6.0% of global mortality) and 90.7 million DALYs (95% uncertainty interval, 58.9-123.3 million; 3.2% of DALYs). Although global all-ages rates remained stable, age-standardized death and DALY rates decreased by 45.6% and 39.5%, respectively, since 1990. In 2023, age-standardized LDL-C–attributable DALY rates were highest in Eastern Europe and lowest in high-income Asia-Pacific. One-third of the global LDL-C burden occurred in India and China. Population growth and aging drove the increasing burden, with notable regional disparities in LDL-C exposure and risk-deleted DALY rates shifting toward middle-sociodemographic settings. Conclusions and Relevance Despite declining age-standardized rates, the absolute LDL-C burden has increased since 1990 due to demographic changes and has shifted toward middle-sociodemographic countries. Measurement and surveillance gaps persist. Strengthened prevention, diagnosis, and treatment access strategies are essential to mitigate the health burden of LDL-C.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Institute for Health Metrics and Evaluation (IHME), University of Washington, Seattle, Washington.
- Department of Health Metrics Sciences, School of Medicine, University of Washington, Seattle, Washington.
- Al Zaytoonah University of Jordan, Amman, Jordan.
- University of the West of Scotland, Paisley, United Kingdom.
- University of Nigeria Nsukka, Enugu, Nigeria.
- Alexandria University, Alexandria, Egypt.
Förderung
- World Health Organization
Zitieren
APA
GBD 2023 LDL Cholesterol Collaborators, Razo, C., DeCleene, N. K., Johnson, C. O., Stark, B. A., LeGrand, K., Aalruz, H., Abaraogu, U. O., Abd ElHafeez, S., Abdelmasseh, M., Abdelnabi, M., Abd-Elsalam, S., Abdelsalam Elshenawy, R., Abdelwahab, S. I., Abdolizadeh, A., Abdollahi, A., Abdoun, M., Abdrabou, M. M., Abdulah, D. M., …, & Ahmad, S. (2026). Global Burden of Elevated LDL-C. JAMA, 336(8), 673. https://doi.org/10.1001/jama.2026.8628
Vancouver
GBD 2023 LDL Cholesterol Collaborators, Razo C, DeCleene NK, Johnson CO, Stark BA, LeGrand K, et al. Global Burden of Elevated LDL-C. JAMA. 2026;336(8):673. doi:10.1001/jama.2026.8628
BibTeX
@article{GBDLDLCholesterolCollaborators2026,
author = {GBD 2023 LDL Cholesterol Collaborators, GBD 2023 LDL Cholesterol Collaborators and Razo, Christian and DeCleene, Nicole K and Johnson, Catherine O and Stark, Benjamin A and LeGrand, Kate and Aalruz, Hasan and Abaraogu, Ukachukwu O and Abd ElHafeez, Samar and Abdelmasseh, Michael and Abdelnabi, Mahmoud and Abd-Elsalam, Sherief and Abdelsalam Elshenawy, Rasha and Abdelwahab, Siddig Ibrahim and Abdolizadeh, Ali and Abdollahi, Arash and Abdoun, Meriem and Abdrabou, Mostafa M and Abdulah, Deldar Morad and Abdullahi, Auwal and Abdul-Rahman, Toufik and Abebe, Melese Shenkut and Abebe Getahun, Habtamu and Abiodun, Olugbenga Olusola and Abiodun, Olumide and Abohashem, Shady and Abonie, Ulric Sena and Abourashed, Nagah M and Abramov, Dmitry and Abrar, Mohammed Mehdi and Abtahi, Dariush and Abu Farha, Rana Kamal and Abubakar, Bilyaminu and Abuhelwa, Ahmad Y and Abukhadijah, Hana J and Aburuz, Salahdein and Abushanab, Dina and Adams, Lisa C and Adamu, Nuhu Lawan Lawan and Adane, Mesafint Molla and Addo, Isaac Yeboah and Adedokun, Kamoru Ademola and Adegbile, Oluwatobi E and Adegoke, Nurudeen A and Adekola, Saheed Ayodeji and Adeleke, Olumide Thomas and Adesina, Miracle Ayomikun and Adisu, Molalign Aligaz and Adnan, Mohd and Afoakwah, Clifford and Afolabi, Aanuoluwapo Adeyimika and Afrashteh, Fatemeh and Afrifa-Yamoah, Ebenezer and Afzal, Saira and Agordoh, Percival Delali and Agyemang-Duah, Williams and Ahmad, Aqeel and Ahmad, Khabir and Ahmad, Sajjad and Ahmad, Suhaib},
title = {Global Burden of Elevated LDL-C},
journal = {JAMA},
year = {2026},
volume = {336},
number = {8},
pages = {673},
doi = {10.1001/jama.2026.8628}
}
EUVIMED